The effect of autogenous concentration growth factor partly external use in facial rejuvenation

The safety and efficacy of autogenous growth factor partly external use in facial rejuvenation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043435

Enrollment

Unknown

Registered

2021-02-17

Start date

2021-02-17

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial aging

Interventions

treatment group:autogenous concentration growth factor partly external use

control group :Regular Facial Care

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 40 and 70; (2) Skin Fitzpatrick type III or IV; (3) Have the need and willingness for facial rejuvenation, sign the informed consent of clinical trial voluntarily, and actively cooperate with treatment and follow visitors; (4) There is no deformity or scar on the face, and the aging degree on both sides of the face is the same; (5) No skin system diseases; (6) The ongoing treatment of the study subjects has no effect on this study.

Exclusion criteria

Exclusion criteria: (1) Have received facial surgery (such as Botox injection, subcutaneous filling, chemical stripping, electro-optic therapy, etc.) within 6 months prior to the date of operation; (2) There were herpes simplex virus infection, facial eczema, facial trauma, facial infection, facial neuritis and trigeminal neuralgia on the face during the trial; (3) Ultraviolet light sensitivity and scar constitution; (4) Pregnant or lactating women, women who plan to become pregnant during the study period; (5) Coagulation dysfunction; (6) autoimmune diseases such as: Hashimoto's disease, rheumatoid arthritis; (7) Patients with severe organic diseases, such as coronary heart disease, hypertension, diabetes, pulmonary dysfunction and other unstable disease control; (8) Malignant tumor; (9) People suffering from acute or chronic infectious diseases, mental diseases and mental disorders.

Design outcomes

Primary

Measure	Time frame
Facial VISIA test;	—

Secondary

Measure	Time frame
Anterior and lateral high resolution facial photography;Facial four-dimensional color ultrasound;Skin spectrophotometer test;facial winkle scale;wrinkle severity rating scale;glabellar line severity score;Face -Q Appearance Assessment Scale;Face -Q Quality of Life Scale;Subjective satisfaction with treatment;Self-assessment Questionnaire;	—

Countries

China

Contacts

Public ContactPei Bin

Xiangyang No.1 People's Hospital, affiliated hospital of Hubei University of Medicine

binpei@hbmu.edu.cn+86 18995678520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026